Although I am already heavily overweight TRS, I bought another decent parcel today. While we are all in the dark until the next announcement, the facts as I see them make the current price too good to pass up. If we assume the company will hit guidance this year, there should be a minimum $2m upside next year from the benefits of the HK office, DC ramp up, and an improved Q1. Things can always go awry, but I can't see patient holders being disappointed at the current share price if they are prepared to ride out the volatility.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$6.68 |
Change
0.020(0.30%) |
Mkt cap ! $249.6M | |||
| Open | High | Low | Value | Volume |
| $6.66 | $6.68 | $6.66 | $927.6K | 139.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 48915 | $6.67 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $6.68 | 17411 | 2 |
View Market Depth
| Last trade - 16.19pm 25/06/2025 (20 minute delay) ? |
| TRS (ASX) Chart |